Effects of tetrandrine on smooth muscle contraction induced by mediators in pulmonary hypertension

Acta Pharmacologica Sinica

Volumn 23, Issue 12, 2002, Pages 1114-1120

  Wang, Huai Liang ^a   Zhang, Xin Hua ^a   Chang, Tian Hui ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II; Endothelin 1; Histamine; Leukotriene C4; Leukotriene D4; Leukotriene E4; Neuropeptide Y; Pulmonary artery; Tetrandrine; Thromboxane A2

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ANGIOTENSIN; ARACHIDONIC ACID; BISBENZYLISOQUINOLINE ALKALOID; BOSENTAN; CALCIUM CHANNEL STIMULATING AGENT; CARBACHOL; CHINESE DRUG; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; FURTRETHONIUM; HERBACEOUS AGENT; HISTAMINE; LEUKOTRIENE C4; LEUKOTRIENE D4; NEUROPEPTIDE Y; PARGYLINE; PHENOXYBENZAMINE; TETRANDRINE; THROMBOXANE A2 RECEPTOR STIMULATING AGENT; YOHIMBINE;

ANIMAL TISSUE; CHINESE MEDICINE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GUINEA PIG; LUNG ARTERY; NONHUMAN; PULMONARY HYPERTENSION; RAT; TRACHEA; VASCULAR RING; VASCULAR SMOOTH MUSCLE;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; 3-PYRIDINECARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-5-NITRO-4-(2-(TRIFLUOROMETHYL)PHENYL)-, METHYL ESTER; ALKALOIDS; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZYLISOQUINOLINES; ENDOTHELIN-1; GUINEA PIGS; HYPERTENSION, PULMONARY; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NEUROPEPTIDE Y; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; SRS-A;

EID: 0036905942     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Achike FI, Kwan CY. Characterization of a novel tetrandrine-induced contraction in rat tail artery. Acta Pharmacol Sin 2002; 23: 698-704.
2. Wang HL, Liu KJ, Zhang XH, Jin X, Xing J. Effects of tetrandrine on acute hypoxic pulmonary hypertension. Chin J Pharmacol Toxicol 1994; 8: 246-9.
3. Wang HL, Liu KJ, Zhang XH, Jin X, Xing J. Effect of tetrandrine on monocrotaline-induced pulmonary hypertension in the rat. Acta Pharmacol Sin 1997; 18: 400-4.
4. Wang HL, Liu KJ, Zhang XH, Jin X, Xing J. Tetrandrine inhibits chronic "inflammatory" pulmonary hypertension in rats. Drug Dev Res USA 1997; 39: 159-60.
5. Wang HL, Kilfeather SA, Page CP, Martin GR, Pogson CI. Effect of tetrandrine on growth factor-induced DNA synthesis and proliferation of rat pulmonary arterial smooth cells. J Pulmonary Pharmacol Ther 2000; 13: 53-60.
6. Barnes PJ, Baraniuk J, Belvisi MG. Neuropeptides in the respiratory tract. Am Rev Respir Dis 1991; 144: 1187-98.
7. Ono S, Voelkel NF. PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension. J Appl Physiol 1991; 71: 2483-92.
8. Jin XR, Fan M, Wang ZQ, Su YC, Yang GT, Hu HB, et al. Strain difference in pulmonary vascular responsiveness to hypoxia in rats. J Tongji Med Univ 1990; 10: 134-40.
9. Lippton HL, Hamari C, Feng CJ, Chen BQ, Summer WR. Peptidergic regulation of the lung circulation. Crit Care Report 1990; 1: 266-74.
10. Soifer SJ, Schreiber MD, Heymann MA. Leukotriene antagonists attenuate thromboxane-induced pulmonary hypertension. Pediatr Res 1990; 26: 83-7.
11. Krell DR, Osborn R, Vickery L, Falcone K, Gleason J. Contraction of isolated airway smooth muscle by synthetic leukotrienes C4 and D4. Prostaglandins 1981; 22: 387-409.
12. Van Rossum JM. Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn Ther 1963; 143: 229-330.
13. Ibe BO, Campbell WD. Synthesis and metabolism of leukotrienes by human endothelial cells, influence on prostacyclin release. Biochem Biophys Acta 1988; 960: 309-21.
14. Boot JR, Bond AR, Gooderham R, O'Brien A, Parsons M, Thomas KH. The pharmacological evaluation of LY170680, a novel leukotriene D4 and E4 antagonist in guinea-pig. Br J Pharmacol 1989; 98: 259-67.
15. 2+ channels. Trends Pharmacol Sci 1991; 12: 349-53.
16. Marks AR. Calcium channels expressed in vascular smooth muscle. Circulation 1992; 86 Suppl III: 61-7.
17. McMurtry IF. Humoral Control in Abnormal Pulmonary Circulation. Bergosfky EH, editor. Philadelphia: Churchill Livingstone: 1986. p 83-125.
18. Fang DC, Xia GJ, Qu L, Jiang MX. Studies on the calcium antagonist action of tetrandrine. I. Effects of tetrandrine on the isolated guinea pig atrium. Acta Acad Med Wuhan 1981; 1: 46-50.
19. Wang G, Zong XG, Fang DC, Jiang MX, Lu FH. Effects of tetrandrine on the slow inward currents in canine cardiac Pukinje fibres. Acta Pharm Sin 1988; 23: 646-50.
20. Felix JP, King VF, Shevell JL, Garcia ML, Kaczorowski GJ, Bick IRC, et al. Bis-benzylisoquinoline analogs of tetrandrine block L-type calcium channels: Evidence for interaction at the diltiazem-binding site. Biochemistry 1992; 31: 11793-800.
21. Shimamoto Y, Shimamoto H, Kwan CY, Danniel EE. Differential effects of putative protein kinase C inhibitors on contraction of rat aortic smooth muscle. Am J Physiol 1993; 264: H1300-6.
22. Voelkel NF, Stenmark KR, Reeves JT, Mathias MM, Murphy RC. Actions of lipoxygenase metabolites in isolated rat lungs. J Appl Physiol 1984; 57: 860-7.